These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7126427)

  • 21. Lynestrenol 1 mg.-mestranol 0.1 mg: a new low dose oral contraceptive: a clinical study.
    Kamal I; Hefnawi F; Younis N
    Egypt Popul Fam Plann Rev; 1970 Jun; 3(1):11-5. PubMed ID: 12254506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Contraception and subsequent fertility. Results of a retrospective study].
    Spira N; Spira A; Schwartz D
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):353-8. PubMed ID: 12280206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study of cholelithiasis during pregnancy and its relationship with age, parity, menarche, breast-feeding, dysmenorrhea, oral contraception and a maternal history of cholelithiasis.
    Basso L; McCollum PT; Darling MR; Tocchi A; Tanner WA
    Surg Gynecol Obstet; 1992 Jul; 175(1):41-6. PubMed ID: 1621198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use.
    Wu ML; Whittemore AS; Paffenbarger RS; Sarles DL; Kampert JB; Grosser S; Jung DL; Ballon S; Hendrickson M; Mohle-Boetani J
    Am J Epidemiol; 1988 Dec; 128(6):1216-27. PubMed ID: 3195563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study.
    Cooper JA; Rohan TE; Cant EL; Horsfall DJ; Tilley WD
    Br J Cancer; 1989 Jan; 59(1):119-25. PubMed ID: 2757918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective study of oral contraceptive use and risk of breast cancer in women.
    Romieu I; Willett WC; Colditz GA; Stampfer MJ; Rosner B; Hennekens CH; Speizer FE
    J Natl Cancer Inst; 1989 Sep; 81(17):1313-21. PubMed ID: 2769784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics that predict risk of breast cancer before and after the menopause.
    Paffenbarger RS; Kampert JB; Chang HG
    Am J Epidemiol; 1980 Aug; 112(2):258-68. PubMed ID: 7416152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum lipid studies in women using combination type of oral contraceptives.
    Vaidya R; Purandare VN; Nain S; Gupta K; Rajwade N; Sheth UK
    J Obstet Gynaecol India; 1979 Jun; 29(3):644-6. PubMed ID: 12335922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for benign breast disease.
    Brinton LA; Vessey MP; Flavel R; Yeates D
    Am J Epidemiol; 1981 Mar; 113(3):203-14. PubMed ID: 7468579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors.
    Holman CD; Armstrong BK; Heenan PJ
    Br J Cancer; 1984 Nov; 50(5):673-80. PubMed ID: 6498065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential study of plasma euglobulin fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen.
    Jespersen J
    Gynecol Obstet Invest; 1983; 15(5):266-74. PubMed ID: 6852646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of age and menstrual cycle upon proliferative activity of the normal human breast.
    Potten CS; Watson RJ; Williams GT; Tickle S; Roberts SA; Harris M; Howell A
    Br J Cancer; 1988 Aug; 58(2):163-70. PubMed ID: 3166907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.
    Olsson H; Lindahl B; Ranstam J; Borg A; Fernö M; Norgren A
    Anticancer Res; 1987; 7(4B):853-6. PubMed ID: 3674773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in insulin receptors during oral contraception.
    De Pirro R; Forte F; Bertoli A; Greco AV; Lauro R
    J Clin Endocrinol Metab; 1981 Jan; 52(1):29-33. PubMed ID: 7451643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reproductive factors and breast cancer.
    Kelsey JL; Gammon MD; John EM
    Epidemiol Rev; 1993; 15(1):36-47. PubMed ID: 8405211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thyroid function tests under the effect of steroidal contraceptives compared to normal pregnancy.
    Nasr EM; El-mekkawi T; Abbas A; El-sheikha Z; Abdel Aziz A
    Popul Sci; 1982; (3):157-68. PubMed ID: 12266214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fertility awareness affects method use.
    Barnett B
    Netw Res Triangle Park N C; 1996; 17(1):9. PubMed ID: 12320448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benign breast tumor and estrogenic hormones: a population-based retrospective study.
    Nomura A; Comstock GW
    Am J Epidemiol; 1976 May; 103(5):439-44. PubMed ID: 179318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Studies on psychophysiological performance in female athletes during menstruation without and with hormonal contraceptives].
    Stecher VH; Beyer L
    Med Sport (Berl); 1986; 26(8):252-4. PubMed ID: 12315369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.